Where Should Enzalutamide Be in The Metastatic Castration Resistant Prostate Cancer (mCRPC): A Multi-center Study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorKoca, Sinan
dc.contributor.authorOkten, Ilker Nihat
dc.contributor.authorBesiroglu, Mehmet
dc.contributor.authorTelli, Tugba Akin
dc.contributor.authorDemirci, Ayse
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorUrvay, Semiha
dc.contributor.authorFirat, Sedat Tarik
dc.contributor.authorOruc, Zeynep
dc.contributor.authorZerey, Mehmet Murat
dc.contributor.authorCoban, Ezgi
dc.contributor.authorCil, Ibrahim
dc.contributor.authorGumus, Mahmut
dc.date.accessioned2025-10-16T15:16:07Z
dc.date.issued2023
dc.identifier.doi10.14744/ejmo.2023.69719
dc.identifier.otherWOS:001135809500007
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6624
dc.publisherKARE PUBL
dc.sourceEURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
dc.subjectprostate cancer
dc.subjectenzalutamide
dc.subjectdocetaxel
dc.subjectline of treatment
dc.titleWhere Should Enzalutamide Be in The Metastatic Castration Resistant Prostate Cancer (mCRPC): A Multi-center Study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS